
There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

This is the peer reviewed version of the following article Sliwa, K., Petrie, M. C., Hilfiker-Kleiner, D., Mebazaa, A., Jackson, A., Johnson, M. R., van der Meer, P., Mbakwem, A. and Bauersachs, J. (2018) Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 20(6), pp. 951-962, which has been published in final form at http://dx.doi.org/10.1002/ejhf.1178. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

http://eprints.gla.ac.uk/157931/

Deposited on: 26 February 2018
Long-term prognosis, subsequent pregnancy, contraception and overall management of Peripartum Cardiomyopathy

Practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Authors: Karen Sliwa (1,2), Mark C Petrie (3), Denise Hilfiker-Kleiner (4), Alexandre Mebazaa (5), Alice Jackson (3), Mark R. Johnson (6), Peter van der Meer (7), Amam Mbakwem (8), Johann Bauersachs (4)

1. Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, Department of Medicine & Cardiology, University of Cape Town, South Africa
2. Mary McKillop Institute, ACU, Melbourne, Australia
3. Golden Jubilee National Hospital, Glasgow, United Kingdom
4. Department of Angiology and Cardiology, Molekular Kardiologie Medizinische Hochschule Hannover, Hannover, Germany
5. Hôpital Lariboisière, Université Paris Diderot, Inserm U 942, Paris, France
6. Department of Obstetrics, Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK;
7. Department of Cardiology, University Medical Center Groningen, The Netherlands
8. Department of Cardiology, Lagos University Hospital, Lagos

Corresponding author: Prof. Karen Sliwa
Hatter Institute for Cardiovascular Research in Africa, Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa.
Email: Karen.Sliwa-Hahnle@uct.ac.za

Keywords: Peripartum Cardiomyopathy, Subsequent pregnancy, mortality

Word Count: 4018 (excluding references, 3 Figures, 2 Tables)
ABSTRACT

PPCM is an idiopathic cardiomyopathy presenting with heart failure secondary to left ventricular systolic dysfunction towards the end of the pregnancy, or in the months following delivery, where no other cause for heart failure is found. Outcome varies from full recovery, to residual left ventricular systolic dysfunction and even death. Many women return to their physician to acquire information on their long-term prognosis, to seek medical advice regarding contraception or when planning a subsequent pregnancy. This position paper summarizes the current evidence for long-term outcome, risk stratification of further pregnancies and overall management. Based on the best available evidence, as well as the clinical experience of the Study Group members, a consensus on pre- and postpartum management algorithms for women undergoing a subsequent pregnancy is presented.
INTRODUCTION

Peripartum Cardiomyopathy (PPCM) is an idiopathic form of cardiomyopathy, presenting with heart failure secondary to left ventricular dysfunction towards the end of pregnancy or in the months following delivery, where no other cause of heart failure is identified. Patients can present with severe acute heart failure with a high morbidity and mortality requiring a multi-disciplinary approach. Even those who present with more subtle symptoms can still have long-term impaired cardiac function. Until recently, data on suspected or confirmed cases of PPCM from Europe and most other regions of the world were limited. However, data from the ongoing EurObservational Research Registry on PPCM have shown that this condition occurs globally. Patients with PPCM are often young, have just started their families and, often, wish to fall pregnant again. The impact of a subsequent pregnancy on clinical outcome is crucial, as it will not only affect the pregnant woman, but also other family members such as her partner and other children under their care. Moreover, after the traumatic experience of PPCM patients may also develop psychological disorders that need treatment.

WHAT IS KNOWN ABOUT THE LONG-TERM OUTCOME OF WOMEN WITH PPCM?

When a woman is diagnosed with PPCM, questions relating to the long-term consequences of the condition commonly arise. Women have described feeling terrified and devastated following a diagnosis of PPCM. They often struggle with recommendations to avoid a further pregnancy and report damaging effects on their marriage and relationships with other family members. In a review of comments from a PPCM support website, several messages were from users searching for information related to recovery, its length of time, the impact of subsequent pregnancies and the duration of medical therapy. Many studies on PPCM have investigated the clinical course over 6 months or a year, but few have investigated outcomes over several years or decades. Women are understandably interested not only in outcomes during the early period following a diagnosis, but also in the long-term prognosis. Risk prediction of normalization of cardiac function and survival beyond 5 years cannot be provided based on solid prospective data. There are also no prospective long-term outcome data on larger cohorts of patients with PPCM that have received a left ventricular assist devices or cardiac transplantation to make clear recommendations on long-term benefit. Much of what we do know comes from small studies of selected populations and from restricted geographical areas (Table 1).
Long-term Mortality

1-6 months postpartum

Outcomes for patients with PPCM appear to be more favourable than for those with other forms of cardiomyopathy. In a comparison of mortality, over a mean follow-up period of 4.4 years in a large single-centre study of 1230 patients with cardiomyopathy, survival was greater in patients with PPCM than in those with idiopathic cardiomyopathy (adjusted HR 0.31, 0.09-0.98). Nonetheless, despite increasing recognition and understanding of PPCM, mortality rates have only been studied in a small number of countries and most available data comes from the USA, South Africa, Haiti, Turkey and Pakistan. There are very few studies from Europe which report outcomes for women with PPCM and these are mainly small case series of n≤12. Most studies to-date have concentrated on mortality at 6 months, with a wide variation in reported rates, ranging from 2% in Germany to 12.6% in a large cohort of 206 patients with PPCM from South Africa. Our current focus is on outcomes beyond 6 months.

6-12 months postpartum

Mortality up to 12 months is 4-14%, with the majority towards the lower end of this range (Table 1). The highest rates of mortality at 6-12 months are seen in African women (12-14%). This racial variation is evident elsewhere. For example, in the IPAC study in the United States (30% self-designated black), mortality at 12 months was 4% while, in Detroit, (96% were African-American women) 11% died at a median follow-up of 12.5 months. A recent trial adding the prolactin blocker bromocriptine on top of standard therapy for heart failure reported an excellent 6 months follow-up outcome in severely diseased patients having over 60% full recovery and 0% mortality, heart transplantation and/or use of assist device.

1-5 years postpartum

Of 182 women from the USA (56% Caucasian, 29% African-American, 10% Hispanic, 3% Asian), mortality was 7% at a mean follow-up of 19 months. A significantly larger proportion of the group who died or underwent cardiac transplantation were non-Caucasian, compared with the rest of the group (76% vs. 39%, p=0.0001). At around 2 years, studies of black populations report mortality of 28% in South Africa, 16% in Louisiana, USA and 15% in Haiti. Similarly, in a small case series of 13 women from New York, of which 69% were non-Caucasian, 23% of women had died at 2.1 years. In other studies from the USA, outcomes for women with PPCM are more favourable, with 2-year mortality of 0-9%. Mortality is also lower in women with PPCM from Brazil (8% at 2.1 years), and China (4% at 2.3 years). Mortality between 2-5 years varies even more considerably, ranging
from 0-6% in French and American women\textsuperscript{9,11,29-32} to 15-30% in women from China,\textsuperscript{33} Brazil,\textsuperscript{34} Turkey,\textsuperscript{35-37} South Africa,\textsuperscript{38} and the Philippines.\textsuperscript{39}

\textit{Beyond 5 years postpartum}

There are few data beyond 5 years for women with PPCM. In 3 studies from the USA mortality ranges from 7-16% at between 7 and 8.6 years.\textsuperscript{9,40,41} In India, mortality was 23% at 6.1 years\textsuperscript{42} and in Malaysia (n=12) 8.3% at 6.4 years.\textsuperscript{43} In a prospective study of 181 Nigerian women with PPCM from 1989, 26% had died at 10 years.\textsuperscript{44} There are no more recent studies of mortality beyond 5 years in African women.

\textbf{Predictors of late mortality and mode of death}

As recently highlighted by Sliwa et al\textsuperscript{45} late maternal death (> 42 days postpartum) is globally poorly reported despite being an ICD10 coding recommendation. Few studies on PPCM with follow-up extending beyond 2 years have sought to identify prognostic indicators in women with PPCM. In Turkey baseline LVEF and LV end systolic diameter were identified as significant predictors of mortality due to heart failure.\textsuperscript{35} These results conflict with other long-term follow-up studies, in which there were no differences in baseline echocardiographic parameters between deceased and surviving study participants.\textsuperscript{1,22}

While much of the existing data suggest that the risk of death is greatest in the early postpartum period, later deaths occurring either due to deterioration of cardiac function or arrhythmia have been noted. Only 36% of deaths occurred within 6 months in a group of 80 women with PPCM from South Africa, with a further 36% at 6-12 months and 27% at 12-24 months.\textsuperscript{21} Notably, in this cohort,\textsuperscript{21} recovery of LV function had occurred in 29% of patients who died between 6-24 months, suggesting that even in those with early recovery, a risk of mortality persisted beyond this.\textsuperscript{21} In a retrospective 2-centre study of 100 women from the USA, 2 out of 11 women who died had recovered LV function by a mean of 23 months and death occurred at a mean of 83 months.\textsuperscript{40} In fact more recent data using wearable cardioverter/defibrillator (WCD) clearly demonstrate a high risk for ventricular tachyarrhythmias (VTA), and sudden death in patients with PPCM is more common in the acute phase of the disease but may even occur during recovery.\textsuperscript{46,47} In general the recommendations of the ESC Guidelines for acute and chronic heart failure on the on the use of wearable cardioverter/defibrillators should be followed\textsuperscript{48}.

However, clear markers to identify patients at risk for arrhythmic death or non-sudden death do not exist. Consequently, although the time at which death occurs following a diagnosis of PPCM is clearly
important with regard to informing patients and also to decide whether or not continued pharmacological or device therapy may be warranted, more research to identify prognostic factors or markers associated with late death in women with PPCM is needed.

**Recovery of left ventricular (LV) function**

**Recovery at 6 months**

Studies of recovery of cardiac function with an echocardiographic left ventricular ejection fraction (LVEF) >45% have largely focussed on the trajectory over the first 6 months postpartum and rates vary markedly from one country to another. Six-month recovery rates between 46-63% have been reported in Japan, China, Turkey, Germany, and the USA. Six-month recovery is worse (21-36%) in South Africa, Nigeria, Pakistan, and the Philippines.

**Recovery beyond 6 months**

Although data on early recovery of LV function is more frequently reported, the concept of myocardial recovery beyond 6 months is increasingly recognised. In the recent Investigations of Pregnancy-Associated Cardiomyopathy (IPAC) study, a prospective multicentre American study of 100 women with PPCM, recovery (LVEF>50%) was seen in 72% of women at 12 months. Rate of recovery between 6 and 12 months is unavailable. In a prospective analysis of a group of 42 Turkish women with PPCM, recovery of LV function beyond 6 months was seen in 44%. Of those who recovered, 60% did so beyond 12 months, with recovery seen up to 42 months postpartum. Similarly, a median time to recovery of 54 months was reported in a retrospective analysis of 44 women with PPCM in Louisiana, USA, with a 30% non-recovery rate reported up to 9 years after diagnosis. Recovery at 6-monthly intervals, up to 36 months, was also illustrated in a cohort of 116 women from Haiti, with 28% of all women regaining good cardiac function. At each follow-up interval, there was a steady increase in the proportion of women who demonstrated recovery of LV function. 53% of recovered patients did so beyond 18 months.

These data illustrate that recovery can occur after 6 months and continuing recovery can be seen, at least in some countries, after several years. However, the current literature is far from comprehensive. More prospective, multicentre studies of myocardial recovery in unselected populations with long-term follow-up are required in order to describe the natural history of cardiac function in women with PPCM. More sophisticated echocardiographic investigation, including strain measurements and cardiac magnetic resonance imaging, would allow more detailed assessment of cardiac function and structure following a diagnosis. To date, recovery of cardiac function has
focussed on LVEF and the long-term effects on right ventricular function have not been studied. There is a need to investigate the long-term effects on mitral incompetence and if PPCM are left with a residual myocardial scar.

**DOES MYOCARDIAL FUNCTION DETERIORATE AFTER STOPPING MEDICAL THERAPY FOR PPCM WITH RECOVERED CARDIAC FUNCTION?**

A common clinical question when myocardial recovery occurs in PPCM is: “Should medical therapy be stopped?” There are few data to guide this decision and, therefore, no recommendations within current guidelines exist. In a prospective, 2-centre study from Turkey investigating recovery in 42 patients with PPCM, 4 patients (2 who had full recovery of LV function and 2 who had partial recovery of LV function) showed delayed deterioration at 12, 24, 26 and 34 months after diagnosis. In the 2 patients who had fully recovered, medication was discontinued when cardiac function improved, although the time at which medical therapy was stopped is not clear. The other 2 patients were still receiving heart failure therapy. The only other observational study is a cohort of women from North Carolina with recovered myocardial function. Of the 5 patients who had discontinued treatment with both beta-blocker and angiotensin converting enzyme inhibitor, none demonstrated deterioration in cardiac function after a mean follow-up of 29 months. There is one further case series describing 3 women from the USA with recovered LV function who had a subsequent deterioration of myocardial function (unrelated to a further pregnancy) ‘several months or years’ later. Whether these women were still receiving medical therapy is not reported. Therefore, studies evaluating criteria for treatment duration (clinical signs, biomarkers) to determine the time and composition of long-term treatment are needed.

**WHAT CAN BE RECOMMENDED FOR THE LONG-TERM MANAGEMENT OF WOMEN WITH PPCM?**

The current recommendation, based on consensus of the PPCM HFA Study Group members, is a six-monthly visit including echocardiography in all women until they recover to an LVEF>50%. In women with LV recovery who remain stable after tapering of heart failure drug therapy an annual visit is recommended for up to 10 years.

Patients with persistently reduced EF should continue treatment with ACE inhibitors, beta blockade and with mineralocorticoid receptor antagonist (MRA) for example ivabradine and sacubitril/valsartan according to the current ESC Guidelines for acute and chronic heart failure. There is no consensus as to whether heart failure medication can be stopped in women with a
recovered left ventricular function or subclinical dysfunction. However, weaning from medication should be performed sequentially with careful and close monitoring of patients clinical and cardiac performance (see table 2, Hilfiker-Kleiner/Bauersachs, EHJ 2015). Some of the Study Group members recommend life-long heart failure therapy at highest dose tolerated based on the fact that deterioration of left ventricular function has been observed in women with normalized cardiac function. If patients display signs of incomplete recovery despite recovered EF such as persistent LV dilatation or reduced myocardial strain, continuation of heart failure drugs (ACE inhibitor, betablocker, MRA) should be considered. Research in this field is urgently needed via carefully conducted studies. Genetic testing may be considered in patients with a family history for cardiomyopathy, as recent studies showed that 15% of PPCM patients carry cardiomyopathy-causing mutations. The presence of TTN truncating variants was significantly correlated with a lower ejection fraction at one year follow up, features important for long-term therapy concepts.

**HOW CAN PATIENTS BE BEST ADVISED ABOUT THE RISKS FOR A SUBSEQUENT PREGNANCY?**

Data on subsequent pregnancies in women with a previously diagnosed PPCM are limited. Table 2 summarizes the studies of women who had a subsequent pregnancy (SSP) after being diagnosed with PPCM. However, the mode of data collection is highly variable with some studies not reporting the ejection fraction of the index pregnancy, nor the cardiac dimensions, left and right ventricular function at the onset of the subsequent pregnancy. Also the date of the last assessment post SSP is highly variable. Therefore, there are enormous gaps in our knowledge. Uri Elkayam recently summarized the available information related to SSP in women with a history of PPCM. One of the largest studies to date, published in the New England Journal of Medicine in 2001, was based on information of 44 women with PPCM and SSP, collected via a retrospective survey of members of the American College of Cardiology. Twenty-eight of these women had a recovered cardiac function, while 16 pregnancies occurred in women with persistent left ventricular dysfunction. All pregnancies were associated with a reduction of mean left ventricular ejection fraction (from 49.9±12 % to 42±13 %, p<0.001), with no mortality in women with normalized EF at onset of a SSP (versus 19% in those women who had impaired systolic function (EF 32.0 ± 2%) at onset of a SSP (p=0.06). In the same study, frequency of premature delivery (11 % versus 37%) and therapeutic abortions (4% versus 25%) was also greater in women with impaired versus recovered cardiac function at onset of SSP. As these data were collected via a retrospective survey, information on medical therapy provided during pregnancy was not available.

A recently published prospective study reported the management and outcome of SSPs in 34 PPCM
patients in Germany, Scotland and South Africa. Persistently reduced LVEF (<50%) prior to entering SSP was present in 47%, while full recovery (LVEF ≥50%) was present in 53% of patients. The majority of these patients were of African ethnicity (75%). Overall relapse rate (LVEF < 50% or death after at least 6 months follow-up) was 56% with 12% (4/34) mortality). All 4 deaths occurred in the women with persistently reduced LVEF prior to SSP. Patients obtaining standard therapy for heart failure, and bromocriptine immediately after delivery, displayed significantly better LVEF at follow-up and a higher rate of full recovery, with no patient dying, compared to patients obtaining standard therapy for heart failure alone. This was independent of African or Caucasian race. Bromocriptine was provided to a number of patients, based on previous research suggesting that the nursing hormone, prolactin, which is highly elevated during delivery, and periodically in nursing mothers, is a key player in the pathophysiology of PPCM. A number of factors, such as oxidative stress, promote the cleavage of prolactin in an antiangiogenic 16kDa-PRL fragment being causally involved in PPCM. Furthermore, experimental studies in mice and small clinical pilot studies suggest a beneficial effect of the prolactin blocker bromocriptine to improve outcome of acute PPCM or prevent relapse after a SSP. Recent data from the EuroObs PPCM global registry has demonstrated that of 411 patients, 21.1% received bromocriptine in their index pregnancy. However, breastfeeding should be encouraged in women with mild cardiac dysfunction, particularly in areas of poor sanitation and unsafe water supply.

Based on published data and consensus by the HFA PPCM Study Group our position is that full recovery of LVEF before a SSP is associated with lower mortality and better cardiac function at follow-up. However, all patients have a risk of deterioration of cardiac function. Women with impaired LV function at the onset of a SSP have a high risk of relapse, heart failure and death and pregnancy should be avoided.

Data have shown that patients with a history of PPCM could have subclinical cardiac dysfunction demonstrated reduced myocardial strain after recovery in women with PPCM at least 12 months after the diagnosis. There are no published data on the impact on subsequent pregnancy in this group of patients.

Addition of bromocriptine to standard therapy for heart failure immediately after delivery was found to be safe and seemed to be associated with a better outcome of SSPs in African and Caucasian patients.

The current recommendation based on published data and consensus of the HFA PPCM Study Group members on the management of pregnancy and postpartum period in women with a previous PPCM is summarized in Figure 1.
Patients can be stratified according to impaired or recovered left ventricular function at onset of subsequent pregnancy. However, each case would need to be assessed by a multidisciplinary team, which includes a cardiologist, obstetrician, neonatologist, anaesthetist and possibly other specialists. Neonatologists could provide advice on neonatal outcome if delivery needs to occur prematurely. Anaesthetists need to provide input in patients delivering with symptoms and signs of heart failure. In addition, overall health system factors and maternal factors such as e.g. age and sub-clinical thyroid disease need to be considered.

In pregnant women renin-angiotensin receptor inhibitors need to be terminated because of fetal toxicity. In addition Hydralazine/nitrate combination should be used instead of angiotensin blockers for management of heart failure as well prevention of further deterioration. Anticoagulation with low molecular weight heparin during pregnancy in PPCM women with LV dysfunction should be considered.

In terms of pregnancy from an obstetric standpoint, scans for fetal growth should be performed every 4 weeks from week 24. Timing of the delivery, for obstetric reasons, should be driven by the usual parameters including fetal growth restriction or pre-eclampsia. For cardiac reasons, early delivery should be considered with deteriorating cardiac function and particularly with heart failure. Ideally the target would be to reach 37 weeks. However, the best compromise will be achieved by discussion with the multidisciplinary team to balance maternal health and fetal maturity.

**Figure 2.** Provides a check box for all women with a diagnosis of a PPCM - either newly diagnosed or with a PPCM and subsequent pregnancy. Anticoagulation for 6-8 weeks after the delivery could be considered because of the hypercoagulability during this period of time.

**Contraception for women with a recent PPCM and for patients at high risk in a subsequent pregnancy**

Contraceptive counselling should begin early – i.e. as soon as PPCM has been diagnosed. A review on the use of contraceptives in women with heart disease has been published recently by Roos-Hesselink and colleagues. Types of the most commonly used contraceptives are summarized in **Figure 3.** Appropriate advice may be complex and will require the input of both a cardiologist and an obstetrician to identify the optimal approach. As no studies have been performed in women with heart disease, and in particular in women with PPCM, the relative risks and benefits of different contraceptive methods are based on consensus only. As women with PPCM with LV dysfunction are at a substantial risk of thrombo-embolic events, hormonal contraceptives with a pro-thrombotic effect should be avoided. The risk of venous thrombosis is significantly increased (up to 7-fold) by
the oestrogen component in oral contraceptives - irrespective of type of progestin used. However, the risk is in the general population is small in absolute numbers (8-10/10,000 women-years exposure).65,66 The risks of using a combined oral contraceptive must be weighed against that of an unplanned pregnancy. However, since oestrogen-containing oral contraceptives not only increase the risk of venous thrombosis, but also of arterial thrombosis and hypertension,67,68 they are contraindicated in with most forms of cardiac disease, particularly those associated with an increased venous or arterial thrombotic risk, hypertension or ischaemic heart disease. Further, given that the most effective types of contraception are the long-acting reversible forms (intrauterine contraceptive devices or progesterone cutaneous implants) and that they have no prothrombotic effects, this group of contraceptives should be advised in most cases. They are at least as effective as sterilization, the finality of which some women struggle to accept. The progestogen (etonogestrel), implant known as Implanon, has no cardiac effects, is effective and has fewer side-effects, such as irregular bleeding, than other implants.64 The progesterone releasing intrauterine system, Mirena, is preferred to the older copper IUCDS as the majority of users have no periods. Due to high failure rates barrier methods should only be recommended in addition to other contraceptive methods.

In reaching a decision about type of contraception given the significant maternal morbidity and mortality risk of a subsequent pregnancy, the partner of the women should be involved in reaching the decision about type of contraception. In the decision making the following issues should be considered:

1) The risk of pregnancy for the mother and the consequences of an unplanned pregnancy.

2) The impact of any pregnancy on the entire family, which could include to hospitalization due to heart failure, embolic events and death.

3) The risks and benefits of the type of contraception - in particular pro-thrombotic effects.

4) Failure rates of the type of contraception.

5) The availability and affordability of different types of contraception.

6) The individual’s preferences, which may include the option of sterilization for the women or her partner.

7) For the majority of women, a long-acting reversible form such as an intrauterine contraceptive device will be most favourable.
CONCLUSION AND WAY FORWARD

The current evidence for long-term outcome is based mostly on single-centre studies or small registries. All patients with a previously diagnosed PPCM and their partners should receive careful counselling about the longer-term prognosis and undergo a risk stratification if further pregnancies are considered. Patients who undergoing a subsequent pregnancy should be monitored by an experienced multi-disciplinary team throughout the pregnancy and for at least 1 year postpartum. Based on recently published data, women undergoing a subsequent pregnancy with an impaired systolic function are at substantial risk for a relapse and death and should therefore be advised against pregnancy. Breastfeeding is not advisable in cases with severely impaired systolic function. In those patients inhibition of prolactin with bromocriptine should be considered. The ongoing EURObservational Program on PPCM will provide much needed longer-term outcome data.5

Acknowledgements

The authors would like to acknowledge to overall support of the Heart Failure Association of the European Society of Cardiology. We also acknowledge the support of Ms Sylvia Dennis, Hatter Institute for Cardiovascular Research in Africa, in preparing the manuscript.
Legends

Tables: uploaded as separate files

Table 1: Long-term outcome of patients with PPCM

Table 2: Studies of PPCM patients undergoing a subsequent pregnancy

Figures: (in TiFF format 300 pixels and as separate files)

Figure 1: Counselling of women with PPCM regarding subsequent pregnancy and a guide to management.

Figure 2: Post discharge check box for women diagnosed with PPCM

Figure 3: Sketch illustrating different types of contraceptives
References


registry on peripartum cardiomyopathy (PPCM). EuroObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. European journal of heart failure 2017;In press:DOI: 10.1002/ejhf.780.


12. Horgan SJ, Margey R, Brennan DJ, O'Herlihy C, Mahon NG. Natural history, management, and outcomes of peripartum cardiomyopathy: an Irish single-center cohort study. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and
Oceania Perinatal Societies, the International Society of Perinatal Obstet 2013;26:161-5.


The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure 2016.


Click here to access/download
**Supplementary Material**
HFA PPCM Subsequent__Revision3_trackFeb.doc
6 February 2018

Long-term Prognosis and Management of Peripartum Cardiomyopathy (PPCM): Contraception, Subsequent Pregnancy, Drug Treatment. Practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

Word count: 4018 (excluding references, 3 Figures, 2 Tables)

Yours sincerely

Prof. Karen Sliwa
Dear Editorial office

RE: Long-term Prognosis and Management of Peripartum Cardiomyopathy (PPCM): Contraception, Subsequent Pregnancy, Drug Treatment. Practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

The authors confirm that all material is original to this submission.

Yours sincerely

Prof. Karen Sliwa
1. Authorship Responsibility, Criteria, and Contributions

Each author should comply with all criteria below (A, B, and C) and must indicate general and specific contributions and checking the appropriate lines.

[A] By checking this box, I certify the following:

- The manuscript represents valid work and neither it nor another manuscript I have authored with substantially similar content has been published, or is being considered for publication elsewhere, except as described in an attachment.
- If asked, I will provide or fully cooperate in obtaining and providing the data on which the manuscript is based so the editors or their assignees can examine it.

For papers with more than one author, I agree to allow the Corresponding Author to:

- be the principal correspondent with the Editorial Office;
- review the edited manuscript and proof; and
- make decisions about releasing manuscript information to the media, federal agencies, or both.

If I am the only author, I will be the Corresponding Author and agree to handle these responsibilities.

B. The paper under question is being submitted by an ESC Working Group, and a letter of authorization from the ESC will be furnished.

[A] Yes  [ ] No

C. I have given final approval of the submitted manuscript.

[A] Yes  [ ] No

D. I have, or a co-author has, had sufficient access to the data to verify the manuscript's scientific integrity.

[A] Yes  [ ] No
E. I have participated sufficiently in the manuscript to take public responsibility for:

[ ] part of the content
OR
[x] the entire content

F. To qualify for authorship, you must have made substantial contributions to the intellectual content of the paper. Please indicate your specific contribution(s) to the manuscript. Check all items which apply:

[x] conception and design of the research
[x] acquisition of data
[ ] analysis and interpretation of the data
[ ] statistical analysis
[ ] obtaining funding and supervising the work
[x] drafting the manuscript
[ ] critical revision of the manuscript for important intellectual content
[ ] other (please specify)..........................................................................................

2. Acknowledgement Section (For Corresponding Author Only)

Authors should obtain written permission from all individuals who are listed in the Acknowledgements section of the manuscript since readers may infer their endorsement of data and conclusions. The Corresponding Author must complete this part of the form, to certify that:

(1) all persons who have made substantial contributions in the manuscript (e.g. data acquisition, analysis, or writing or editing assistance), but who do not fulfil authorship criteria, are named with their specific contributions in the Acknowledgements section of the manuscript;

(2) all persons named in the Acknowledgements section have provided the Corresponding Author with written permission to be named in the manuscript; and

(3) if an Acknowledgements section is not included, that no other persons have made substantial contributions to this manuscript.

The Corresponding Author must check below, which will serve as certification of the statement in the Acknowledgement section.

[ ] I am the Corresponding Author and I certify that Section 2 is true.
[x] I am a Contributing Author.

3. Your Signature:

Please Email your completed form to the Editorial Office: ejhf.editorialoffice@wiley.com
Manuscript Number:
(for office use only) __________________________

Title of Manuscript: Long-term Prognosis and Management of Peripartum Cardiomyopathy (PPCM): Contraception, Subsequent Pregnancy, Drug Treatment. Practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

First Author’s Name: __________________________

Your Name: (print) __________________________

1. Authorship Responsibility, Criteria, and Contributions

Each author should comply with all criteria below (A, B, and C) and must indicate general and specific contributions and checking the appropriate lines.

A. By checking this box, I certify the following:

- The manuscript represents valid work and neither it nor another manuscript I have authored with substantially similar content has been published, or is being considered for publication elsewhere, except as described in an attachment.
- If asked, I will provide or fully cooperate in obtaining and providing the data on which the manuscript is based so the editors or their assignees can examine it.

For papers with more than one author, I agree to allow the Corresponding Author to:

- be the principal correspondent with the Editorial Office;
- review the edited manuscript and proof; and
- make decisions about releasing manuscript information to the media, federal agencies, or both.

If I am the only author, I will be the Corresponding Author and agree to handle these responsibilities.

B. The paper under question is being submitted by an ESC Working Group, and a letter of authorization from the ESC will be furnished.

[ ] Yes [ ] No

C. I have given final approval of the submitted manuscript.

[ ] Yes [ ] No

D. I have, or a co-author has, had sufficient access to the data to verify the manuscript’s scientific integrity.

[ ] Yes [ ] No
E. I have participated sufficiently in the manuscript to take public responsibility for:

[ ] part of the content

OR

X the entire content

F. To qualify for authorship, you must have made substantial contributions to the intellectual content of the paper. Please indicate your specific contribution(s) to the manuscript. Check all items which apply:

[ ] conception and design of the research

[ ] acquisition of data

[ ] analysis and interpretation of the data

[ ] statistical analysis

[ ] obtaining funding and supervising the work

[ ] drafting the manuscript

X critical revision of the manuscript for important intellectual content

[ ] other (please specify).................................................................

2. Acknowledgement Section (For Corresponding Author Only)

Authors should obtain written permission from all individuals who are listed in the Acknowledgements section of the manuscript since readers may infer their endorsement of data and conclusions. The Corresponding Author must complete this part of the form, to certify that:

(1) all persons who have made substantial contributions in the manuscript (e.g. data acquisition, analysis, or writing or editing assistance), but who do not fulfil authorship criteria, are named with their specific contributions in the Acknowledgements section of the manuscript;

(2) all persons named in the Acknowledgements section have provided the Corresponding Author with written permission to be named in the manuscript; and

(3) if an Acknowledgements section is not included, that no other persons have made substantial contributions to this manuscript.

The Corresponding Author must check below, which will serve as certification of the statement in the Acknowledgement section.

[ ] I am the Corresponding Author and I certify that Section 2 is true.

X I am a Contributing Author.

3. Your Signature:

[Signature]

Please Email your completed form to the Editorial Office: ejhf.editorialoffice@wiley.com

WILEY
Manuscript Number: (for office use only) __________________________________________

Title of Manuscript: Long-term Prognosis and Management of Peripartum Cardiomyopathy (PPCM): Contraception, Subsequent Pregnancy, Drug Treatment. Practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

First Author’s Name: ___Karen Sliwa________________________________________

Your Name: (print) ___Karen Sliwa________________________________________

1. Authorship Responsibility, Criteria, and Contributions

Each author should comply with all criteria below (A, B, and C) and must indicate general and specific contributions and checking the appropriate lines.

[ ] A. By checking this box, I certify the following:

- The manuscript represents valid work and neither it nor another manuscript I have authored with substantially similar content has been published, or is being considered for publication elsewhere, except as described in an attachment.
- If asked, I will provide or fully cooperate in obtaining and providing the data on which the manuscript is based so the editors or their assignees can examine it.

For papers with more than one author, I agree to allow the Corresponding Author to:

- be the principal correspondent with the Editorial Office;
- review the edited manuscript and proof; and
- make decisions about releasing manuscript information to the media, federal agencies, or both.

If I am the only author, I will be the Corresponding Author and agree to handle these responsibilities.

B. The paper under question is being submitted by an ESC Working Group, and a letter of authorization from the ESC will be furnished.

[X] Yes [ ] No

C. I have given final approval of the submitted manuscript.

[X] Yes [ ] No

D. I have, or a co-author has, had sufficient access to the data to verify the manuscript's scientific integrity.

[X] Yes [ ] No
E. I have participated sufficiently in the manuscript to take public responsibility for:

[ ] part of the content
OR
[ ] the entire content

F. To qualify for authorship, you must have made substantial contributions to the intellectual content of the paper. Please indicate your specific contribution(s) to the manuscript. Check all items which apply:

[ ] conception and design of the research
[ ] acquisition of data
[ ] analysis and interpretation of the data
[ ] statistical analysis
[ ] obtaining funding and supervising the work
[ ] drafting the manuscript
[ ] critical revision of the manuscript for important intellectual content
[ ] other (please specify) ........................................................................................................

2. Acknowledgement Section (For Corresponding Author Only)

Authors should obtain written permission from all individuals who are listed in the Acknowledgements section of the manuscript since readers may infer their endorsement of data and conclusions. The Corresponding Author must complete this part of the form, to certify that:

(1) all persons who have made substantial contributions in the manuscript (e.g. data acquisition, analysis, or writing or editing assistance), but who do not fulfil authorship criteria, are named with their specific contributions in the Acknowledgements section of the manuscript;

(2) all persons named in the Acknowledgements section have provided the Corresponding Author with written permission to be named in the manuscript; and

(3) if an Acknowledgements section is not included, that no other persons have made substantial contributions to this manuscript.

The Corresponding Author must check below, which will serve as certification of the statement in the Acknowledgement section.

[ ] I am the Corresponding Author and I certify that Section 2 is true.
[ ] I am a Contributing Author.

3. Your Signature: ________________________________

Please Email your completed form to the Editorial Office: ejhf.editorialoffice@wiley.com
Manuscript Number:
(for office use only) ________________________________

Title of Manuscript: Long-term Prognosis and Management of Peripartum Cardiomyopathy (PPCM): Contraception, Subsequent Pregnancy, Drug Treatment. Practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

First Author’s Name: ____________________________

Karen Sliwa

Your Name: (print) Peter van der Meer

1. Authorship Responsibility, Criteria, and Contributions

Each author should comply with all criteria below (A, B, and C) and must indicate general and specific contributions and checking the appropriate lines.

X] A. By checking this box, I certify the following:

- The manuscript represents valid work and neither it nor another manuscript I have authored with substantially similar content has been published, or is being considered for publication elsewhere, except as described in an attachment.
- If asked, I will provide or fully cooperate in obtaining and providing the data on which the manuscript is based so the editors or their assignees can examine it.

For papers with more than one author, I agree to allow the Corresponding Author to:

- be the principal correspondent with the Editorial Office;
- review the edited manuscript and proof; and
- make decisions about releasing manuscript information to the media, federal agencies, or both.

If I am the only author, I will be the Corresponding Author and agree to handle these responsibilities.

B. The paper under question is being submitted by an ESC Working Group, and a letter of authorization from the ESC will be furnished.

[ ]Yes [X] No

C. I have given final approval of the submitted manuscript.

[X] Yes [ ] No

D. I have, or a co-author has, had sufficient access to the data to verify the manuscript's scientific integrity.

[ X] Yes [ ] No
E. I have participated sufficiently in the manuscript to take public responsibility for:

[ ] part of the content
OR
[X] the entire content

F. To qualify for authorship, you must have made substantial contributions to the intellectual content of the paper. Please indicate your specific contribution(s) to the manuscript. Check all items which apply:

[X] conception and design of the research
[ ] acquisition of data
[ ] analysis and interpretation of the data
[ ] statistical analysis
[ ] obtaining funding and supervising the work
[ ] drafting the manuscript
[X] critical revision of the manuscript for important intellectual content
[ ] other (please specify)........................................................................................................

2. Acknowledgement Section (For Corresponding Author Only)

Authors should obtain written permission from all individuals who are listed in the Acknowledgements section of the manuscript since readers may infer their endorsement of data and conclusions. The Corresponding Author must complete this part of the form, to certify that:

(1) all persons who have made substantial contributions in the manuscript (e.g. data acquisition, analysis, or writing or editing assistance), but who do not fulfil authorship criteria, are named with their specific contributions in the Acknowledgements section of the manuscript;

(2) all persons named in the Acknowledgements section have provided the Corresponding Author with written permission to be named in the manuscript; and

(3) if an Acknowledgements section is not included, that no other persons have made substantial contributions to this manuscript.

The Corresponding Author must check below, which will serve as certification of the statement in the Acknowledgement section.

[ ] I am the Corresponding Author and I certify that Section 2 is true.
[X] I am a Contributing Author.
3. Your Signature: 

Please Email your completed form to the Editorial Office: ejhf.editorialoffice@wiley.com
Title of Manuscript: Long-term Prognosis and Management of Peripartum Cardiomyopathy (PPCM): Contraception, Subsequent Pregnancy, Drug Treatment. Practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

First Author’s Name: Karen Sliwa

Your Name: (print) Mark Johnson

1. Authorship Responsibility, Criteria, and Contributions

Each author should comply with all criteria below (A, B, and C) and must indicate general and specific contributions and checking the appropriate lines.

[x] A. By checking this box, I certify the following:

- The manuscript represents valid work and neither it nor another manuscript I have authored with substantially similar content has been published, or is being considered for publication elsewhere, except as described in an attachment.
- If asked, I will provide or fully cooperate in obtaining and providing the data on which the manuscript is based so the editors or their assignees can examine it.

For papers with more than one author, I agree to allow the Corresponding Author to:

- be the principal correspondent with the Editorial Office;
- review the edited manuscript and proof; and
- make decisions about releasing manuscript information to the media, federal agencies, or both.

If I am the only author, I will be the Corresponding Author and agree to handle these responsibilities.

B. The paper under question is being submitted by an ESC Working Group, and a letter of authorization from the ESC will be furnished.

[ ] Yes [x] No

C. I have given final approval of the submitted manuscript.

[x] Yes [ ] No

D. I have, or a co-author has, had sufficient access to the data to verify the manuscript’s scientific integrity.

[x] Yes [ ] No
E. I have participated sufficiently in the manuscript to take public responsibility for:

[ ] part of the content
OR
[x] the entire content

F. To qualify for authorship, you must have made substantial contributions to the intellectual content of the paper. Please indicate your specific contribution(s) to the manuscript. Check all items which apply:

[ ] conception and design of the research
[ ] acquisition of data
[ ] analysis and interpretation of the data
[ ] statistical analysis
[ ] obtaining funding and supervising the work
[x] drafting the manuscript
[x] critical revision of the manuscript for important intellectual content
[ ] other (please specify).............................................................................................................

2. Acknowledgement Section (For Corresponding Author Only)

Authors should obtain written permission from all individuals who are listed in the Acknowledgements section of the manuscript since readers may infer their endorsement of data and conclusions. The Corresponding Author must complete this part of the form, to certify that:

(1) all persons who have made substantial contributions in the manuscript (e.g. data acquisition, analysis, or writing or editing assistance), but who do not fulfil authorship criteria, are named with their specific contributions in the Acknowledgements section of the manuscript;

(2) all persons named in the Acknowledgements section have provided the Corresponding Author with written permission to be named in the manuscript; and

(3) if an Acknowledgements section is not included, that no other persons have made substantial contributions to this manuscript.

The Corresponding Author must check below, which will serve as certification of the statement in the Acknowledgement section.

[ ] I am the Corresponding Author and I certify that Section 2 is true.
[ ] I am a Contributing Author.

3. Your Signature: ___________________________
Please Email your completed form to the Editorial Office:
ejhf.editorialoffice@wiley.com
1. Authorship Responsibility, Criteria, and Contributions

Each author should comply with all criteria below (A, B, and C) and must indicate general and specific contributions and checking the appropriate lines.

[x] A. By checking this box, I certify the following:

- The manuscript represents valid work and neither it nor another manuscript I have authored with substantially similar content has been published, or is being considered for publication elsewhere, except as described in an attachment.
- If asked, I will provide or fully cooperate in obtaining and providing the data on which the manuscript is based so the editors or their assignees can examine it.

For papers with more than one author, I agree to allow the Corresponding Author to:

- be the principal correspondent with the Editorial Office;
- review the edited manuscript and proof; and
- make decisions about releasing manuscript information to the media, federal agencies, or both.

If I am the only author, I will be the Corresponding Author and agree to handle these responsibilities.

B. The paper under question is being submitted by an ESC Working Group, and a letter of authorization from the ESC will be furnished.

[ ] Yes [ ] No

C. I have given final approval of the submitted manuscript.

[x] Yes [ ] No

D. I have, or a co-author has, had sufficient access to the data to verify the manuscript's scientific integrity.

[x] Yes [ ] No
E. I have participated sufficiently in the manuscript to take public responsibility for:

[ ] part of the content
OR
[x] the entire content

F. To qualify for authorship, you must have made substantial contributions to the intellectual content of the paper. Please indicate your specific contribution(s) to the manuscript. Check all items which apply:

[ x] conception and design of the research
[ ] acquisition of data
[ x] analysis and interpretation of the data
[ ] statistical analysis
[ ] obtaining funding and supervising the work
[x] drafting the manuscript
[x] critical revision of the manuscript for important intellectual content
[ ] other (please specify) ..............................................................................................

2. Acknowledgement Section (For Corresponding Author Only)

Authors should obtain written permission from all individuals who are listed in the Acknowledgements section of the manuscript since readers may infer their endorsement of data and conclusions. The Corresponding Author must complete this part of the form, to certify that:

(1) all persons who have made substantial contributions in the manuscript (e.g. data acquisition, analysis, or writing or editing assistance), but who do not fulfil authorship criteria, are named with their specific contributions in the Acknowledgements section of the manuscript;

(2) all persons named in the Acknowledgements section have provided the Corresponding Author with written permission to be named in the manuscript; and

(3) if an Acknowledgements section is not included, that no other persons have made substantial contributions to this manuscript.

The Corresponding Author must check below, which will serve as certification of the statement in the Acknowledgement section.

[ ] I am the Corresponding Author and I certify that Section 2 is true.
[x ] I am a Contributing Author.

3. Your Signature: ___________________________
Manuscript Number:
(for office use only) ________________________________

Title of Manuscript: Long-term Prognosis and Management of Peripartum Cardiomyopathy (PPCM): Contraception, Subsequent Pregnancy, Drug Treatment. Practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

First Author’s Name: _______Karen Sliwa_____________________________________________________________________

Your Name: (print) _______Johann Bauersachs_____________________________________________________________________

1. Authorship Responsibility, Criteria, and Contributions

Each author should comply with all criteria below (A, B, and C) and must indicate general and specific contributions and checking the appropriate lines.

[X] A. By checking this box, I certify the following:

- The manuscript represents valid work and neither it nor another manuscript I have authored with substantially similar content has been published, or is being considered for publication elsewhere, except as described in an attachment.
- If asked, I will provide or fully cooperate in obtaining and providing the data on which the manuscript is based so the editors or their assignees can examine it.

For papers with more than one author, I agree to allow the Corresponding Author to:

- be the principal correspondent with the Editorial Office;
- review the edited manuscript and proof; and
- make decisions about releasing manuscript information to the media, federal agencies, or both.

If I am the only author, I will be the Corresponding Author and agree to handle these responsibilities.

B. The paper under question is being submitted by an ESC Working Group, and a letter of authorization from the ESC will be furnished.

[X] Yes [ ] No

C. I have given final approval of the submitted manuscript.

[X] Yes [ ] No

D. I have, or a co-author has, had sufficient access to the data to verify the manuscript’s scientific integrity.

[X] Yes [ ] No
E. I have participated sufficiently in the manuscript to take public responsibility for:

[ ] part of the content

OR

[X] the entire content

F. To qualify for authorship, you must have made substantial contributions to the intellectual content of the paper. Please indicate your specific contribution(s) to the manuscript. Check all items which apply:

[ ] conception and design of the research

[ ] acquisition of data

[ ] analysis and interpretation of the data

[ ] statistical analysis

[ ] obtaining funding and supervising the work

[X] drafting the manuscript

[X] critical revision of the manuscript for important intellectual content

[ ] other (please specify)........................................................................................................................................

2. Acknowledgement Section (For Corresponding Author Only)

Authors should obtain written permission from all individuals who are listed in the Acknowledgements section of the manuscript since readers may infer their endorsement of data and conclusions. The Corresponding Author must complete this part of the form, to certify that:

(1) all persons who have made substantial contributions in the manuscript (e.g. data acquisition, analysis, or writing or editing assistance), but who do not fulfil authorship criteria, are named with their specific contributions in the Acknowledgements section of the manuscript;

(2) all persons named in the Acknowledgements section have provided the Corresponding Author with written permission to be named in the manuscript; and

(3) if an Acknowledgements section is not included, that no other persons have made substantial contributions to this manuscript.

The Corresponding Author must check below, which will serve as certification of the statement in the Acknowledgement section.

[ ] I am the Corresponding Author and I certify that Section 2 is true.

[X ] I am a Contributing Author.
3. Your Signature:

Please Email your completed form to the Editorial Office: ejhf.editorialoffice@wiley.com
Manuscript Number: 
(for office use only)  

Title of Manuscript:  Long-term Prognosis and Management of Peripartum Cardiomyopathy (PPCM): Contraception, Subsequent Pregnancy, Drug Treatment. Practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

First Author’s Name: 
___Karen Sliwa__________________________

Your Name:  (print)  
___________Alice Jackson____________________

1. Authorship Responsibility, Criteria, and Contributions

Each author should comply with all criteria below (A, B, and C) and must indicate general and specific contributions and checking the appropriate lines.

A. By checking this box, I certify the following:

- The manuscript represents valid work and neither it nor another manuscript I have authored with substantially similar content has been published, or is being considered for publication elsewhere, except as described in an attachment.
- If asked, I will provide or fully cooperate in obtaining and providing the data on which the manuscript is based so the editors or their assignees can examine it.

For papers with more than one author, I agree to allow the Corresponding Author to:

- be the principal correspondent with the Editorial Office;
- review the edited manuscript and proof; and
- make decisions about releasing manuscript information to the media, federal agencies, or both.

If I am the only author, I will be the Corresponding Author and agree to handle these responsibilities.

B. The paper under question is being submitted by an ESC Working Group, and a letter of authorization from the ESC will be furnished.

Yes [ ] No

C. I have given final approval of the submitted manuscript.

Yes [ ] No

D. I have, or a co-author has, had sufficient access to the data to verify the manuscript’s scientific integrity.

Yes [ ] No
E. I have participated sufficiently in the manuscript to take public responsibility for:
   part of the content
   OR
   [ ] the entire content

F. To qualify for authorship, you must have made substantial contributions to the intellectual content of the paper. Please indicate your specific contribution(s) to the manuscript. Check all items which apply:
   [ ] conception and design of the research  
   acquisition of data  
   analysis and interpretation of the data  
   [ ] statistical analysis  
   [ ] obtaining funding and supervising the work  
   drafting the manuscript  
   critical revision of the manuscript for important intellectual content  
   [ ] other (please specify)………………………………………………………………………

2. Acknowledgement Section (For Corresponding Author Only)

Authors should obtain written permission from all individuals who are listed in the Acknowledgements section of the manuscript since readers may infer their endorsement of data and conclusions. The Corresponding Author must complete this part of the form, to certify that:

(1) all persons who have made substantial contributions in the manuscript (e.g. data acquisition, analysis, or writing or editing assistance), but who do not fulfil authorship criteria, are named with their specific contributions in the Acknowledgements section of the manuscript;

(2) all persons named in the Acknowledgements section have provided the Corresponding Author with written permission to be named in the manuscript; and

(3) if an Acknowledgements section is not included, that no other persons have made substantial contributions to this manuscript.

The Corresponding Author must check below, which will serve as certification of the statement in the Acknowledgement section.

[ ] I am the Corresponding Author and I certify that Section 2 is true.
I am a Contributing Author.

3. Your Signature: __________________________Alice M Jackson____________________________

Please Email your completed form to the Editorial Office: ejhf.editorialoffice@wiley.com
Title of Manuscript: Long-term Prognosis and Management of Peripartum Cardiomyopathy (PPCM): Contraception, Subsequent Pregnancy, Drug Treatment. Practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy

First Author’s Name: Karen Sliwa

Your Name: Denise Hilfiker-Kleiner

1. Authorship Responsibility, Criteria, and Contributions

Each author should comply with all criteria below (A, B, and C) and must indicate general and specific contributions and checking the appropriate lines.

[X ] A. By checking this box, I certify the following:

- The manuscript represents valid work and neither it nor another manuscript I have authored with substantially similar content has been published, or is being considered for publication elsewhere, except as described in an attachment.
- If asked, I will provide or fully cooperate in obtaining and providing the data on which the manuscript is based so the editors or their assignees can examine it.

For papers with more than one author, I agree to allow the Corresponding Author to:

- be the principal correspondent with the Editorial Office;
- review the edited manuscript and proof; and
- make decisions about releasing manuscript information to the media, federal agencies, or both.

If I am the only author, I will be the Corresponding Author and agree to handle these responsibilities.

B. The paper under question is being submitted by an ESC Working Group, and a letter of authorization from the ESC will be furnished.

[X] Yes  [ ] No

C. I have given final approval of the submitted manuscript.

[ ] Yes  [X] No

D. I have, or a co-author has, had sufficient access to the data to verify the manuscript's scientific integrity.

[X] Yes  [ ] No
E. I have participated sufficiently in the manuscript to take public responsibility for:

[X ] part of the content

OR

[ ] the entire content

F. To qualify for authorship, you must have made substantial contributions to the intellectual content of the paper. Please indicate your specific contribution(s) to the manuscript. Check all items which apply:

[X ] conception and design of the research

[X ] acquisition of data

[ ] analysis and interpretation of the data

[ ] statistical analysis

[ ] obtaining funding and supervising the work

[X ] drafting the manuscript

[X ] critical revision of the manuscript for important intellectual content

[ ] other (please specify)...........................................................................................................................................

2. Acknowledgement Section (For Corresponding Author Only)

Authors should obtain written permission from all individuals who are listed in the Acknowledgements section of the manuscript since readers may infer their endorsement of data and conclusions. The Corresponding Author must complete this part of the form, to certify that:

(1) all persons who have made substantial contributions in the manuscript (e.g. data acquisition, analysis, or writing or editing assistance), but who do not fulfil authorship criteria, are named with their specific contributions in the Acknowledgements section of the manuscript;

(2) all persons named in the Acknowledgements section have provided the Corresponding Author with written permission to be named in the manuscript; and

(3) if an Acknowledgements section is not included, that no other persons have made substantial contributions to this manuscript.

The Corresponding Author must check below, which will serve as certification of the statement in the Acknowledgement section.

[ ] I am the Corresponding Author and I certify that Section 2 is true.

[X ] I am a Contributing Author.

3. Your Signature: __________________________

Please Email your completed form to the Editorial Office: ejhf.editorialoffice@wiley.com
Click here to access/download Supplementary Material coi_disclosure_form_Sliwa.pdf
Click here to access/download Supplementary Material coi_disclosure_AMJ.pdf
Click here to access/download
Supplementary Material
coi_disclosure_Bauersachs.pdf
Click here to access/download
Supplementary Material
coi_disclosure_Hilfiker-Kleiner.pdf
Click here to access/download

Supplementary Material

coi_disclosure_Johnson.pdf
Click here to access/download Supplementary Material
coi_disclosure_Mark_Petrie.pdf
Click here to access/download
**Supplementary Material**
coi_disclosure_Mebazaa.pdf
Click here to access/download
Supplementary Material
coi_disclosure_PvdM.pdf
<table>
<thead>
<tr>
<th>First author</th>
<th>Year</th>
<th>Study period</th>
<th>Location</th>
<th>Study type</th>
<th>Number</th>
<th>Mean age (years)</th>
<th>Mortality (%)</th>
<th>Follow-up in months/years (mean or median)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-12 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Libhaber</td>
<td>2015</td>
<td>2008-2014</td>
<td>South Africa</td>
<td>Prospective, 2 centres</td>
<td>206</td>
<td>30</td>
<td>12</td>
<td>6 m</td>
</tr>
<tr>
<td>Hagikhia</td>
<td>2013</td>
<td>2004-2012</td>
<td>Germany, Hannover</td>
<td>Prospective, 1 centre</td>
<td>115</td>
<td>34</td>
<td>2</td>
<td>6 m</td>
</tr>
<tr>
<td>Barbosa</td>
<td>2012</td>
<td>NA</td>
<td>Brazil</td>
<td>Prospective, 1 centre</td>
<td>9</td>
<td>29</td>
<td>0</td>
<td>7.9 m</td>
</tr>
<tr>
<td>Isezuo</td>
<td>2006</td>
<td>2003-2005</td>
<td>Sokoto, Nigeria</td>
<td>Prospective, 1 centre</td>
<td>65</td>
<td>28</td>
<td>12</td>
<td>9.7 m</td>
</tr>
<tr>
<td>Desai</td>
<td>1995</td>
<td>1986-1989</td>
<td>Durban, South Africa</td>
<td>Retrospective, 1 centre</td>
<td>97</td>
<td>29</td>
<td>14</td>
<td>7 m</td>
</tr>
<tr>
<td>Kamiya</td>
<td>2011</td>
<td>2007-2008</td>
<td>Japan</td>
<td>Survey, nationwide</td>
<td>102</td>
<td>32</td>
<td>4</td>
<td>9.4 m</td>
</tr>
<tr>
<td>Ravikshore</td>
<td>1991</td>
<td>NA</td>
<td>New Delhi, India</td>
<td>Prospective, NA</td>
<td>20</td>
<td>28</td>
<td>5</td>
<td>10 m</td>
</tr>
<tr>
<td>12-23 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Briasoulis</td>
<td>2016</td>
<td>2009-2014</td>
<td>Detroit, USA</td>
<td>Retrospective, 1 centre</td>
<td>47</td>
<td>29</td>
<td>11</td>
<td>12.5 m</td>
</tr>
<tr>
<td>McNamara</td>
<td>2015</td>
<td>2009-2012</td>
<td>USA</td>
<td>Prospective, multicentre</td>
<td>100</td>
<td>30</td>
<td>4</td>
<td>12 m</td>
</tr>
<tr>
<td>Goland</td>
<td>2013</td>
<td>1993-2007</td>
<td>Louisiana + South California, USA</td>
<td>Retrospective, 2 centre</td>
<td>156</td>
<td>29</td>
<td>7</td>
<td>19 m</td>
</tr>
<tr>
<td>Goland</td>
<td>2009</td>
<td>NA</td>
<td>USA</td>
<td>Retrospective, NA</td>
<td>182</td>
<td>29</td>
<td>7</td>
<td>19 m</td>
</tr>
<tr>
<td>Bernstein</td>
<td>2001</td>
<td>1985-1995</td>
<td>Connecticut + New York, USA</td>
<td>Retrospective, 2 centre</td>
<td>23</td>
<td>30</td>
<td>13</td>
<td>12 m</td>
</tr>
<tr>
<td>O’Connell</td>
<td>1986</td>
<td>NA</td>
<td>Illinois, USA</td>
<td>Prospective, 1 centre</td>
<td>14</td>
<td>28</td>
<td>43</td>
<td>12.1 m</td>
</tr>
<tr>
<td>Carvalho</td>
<td>1989</td>
<td>1982-1988</td>
<td>Sao Paulo, Brazil</td>
<td>Prospective, 1 centre</td>
<td>19</td>
<td>26</td>
<td>16</td>
<td>21 m</td>
</tr>
<tr>
<td>Prasad</td>
<td>2014</td>
<td>2006-2012</td>
<td>Maharashtra, India</td>
<td>Prospective, 1 centre</td>
<td>16</td>
<td>25</td>
<td>6</td>
<td>12 m</td>
</tr>
<tr>
<td>~ 2 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cooper</td>
<td>2012</td>
<td>2002-2008</td>
<td>USA</td>
<td>Prospective, multicentre</td>
<td>39</td>
<td>30</td>
<td>0</td>
<td>2.1 y</td>
</tr>
<tr>
<td>Modi</td>
<td>2009</td>
<td>1992-2003</td>
<td>Louisiana, USA</td>
<td>Retrospective, 1 centre</td>
<td>44</td>
<td>25</td>
<td>16</td>
<td>2 y</td>
</tr>
<tr>
<td>Elkayam</td>
<td>2005</td>
<td>1997-1998</td>
<td>USA</td>
<td>Survey, American College of Cardiology</td>
<td>100</td>
<td>30</td>
<td>9</td>
<td>2 y</td>
</tr>
<tr>
<td>van Hoeven</td>
<td>1993</td>
<td>1982-1990</td>
<td>New York, USA</td>
<td>Retrospective, 1 centre</td>
<td>13</td>
<td>30</td>
<td>23</td>
<td>2.1 y</td>
</tr>
<tr>
<td>Cole</td>
<td>1987</td>
<td>NA</td>
<td>Boston, USA</td>
<td>Prospective, NA</td>
<td>14</td>
<td>30</td>
<td>7</td>
<td>2 y</td>
</tr>
<tr>
<td>Fett</td>
<td>2005</td>
<td>2000-2005</td>
<td>Haiti</td>
<td>Prospective, 1 centre</td>
<td>98</td>
<td>32</td>
<td>15</td>
<td>2.2 y</td>
</tr>
<tr>
<td>Moreira</td>
<td>2005</td>
<td>1994-2002</td>
<td>Sao Paulo, Brazil</td>
<td>Retrospective, 1 centre</td>
<td>12</td>
<td>24</td>
<td>8</td>
<td>2.2 y</td>
</tr>
<tr>
<td>Sliwa</td>
<td>2011</td>
<td>2006-2010</td>
<td>Soweto, South Africa</td>
<td>Prospective, 1 centre</td>
<td>80</td>
<td>29</td>
<td>28</td>
<td>2 y</td>
</tr>
<tr>
<td>Liu</td>
<td>2016</td>
<td>1983-2014</td>
<td>Beijing, China</td>
<td>Retrospective, 1 centre</td>
<td>28</td>
<td>27</td>
<td>4</td>
<td>2.3 y</td>
</tr>
<tr>
<td>2.5-5 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gunderson</td>
<td>2011</td>
<td>1995-2004</td>
<td>North California, USA</td>
<td>Retrospective, population</td>
<td>110</td>
<td>NA</td>
<td>2</td>
<td>3 y</td>
</tr>
<tr>
<td>Habli</td>
<td>2008</td>
<td>2000-2006</td>
<td>Ohio + Kentucky, USA</td>
<td>Retrospective, 2 centre</td>
<td>70</td>
<td>NA</td>
<td>0</td>
<td>3.4 y</td>
</tr>
<tr>
<td>Brar</td>
<td>2007</td>
<td>1996-2005</td>
<td>South California, USA</td>
<td>Retrospective, population</td>
<td>60</td>
<td>33</td>
<td>3</td>
<td>4.7 y</td>
</tr>
<tr>
<td>Amos</td>
<td>2006</td>
<td>1990-2003</td>
<td>North Carolina, USA</td>
<td>Retrospective, 1 centre</td>
<td>55</td>
<td>29</td>
<td>0</td>
<td>3.6 y</td>
</tr>
<tr>
<td>Felker</td>
<td>2000</td>
<td>1982-1997</td>
<td>Baltimore, USA</td>
<td>Retrospective, 1 centre</td>
<td>51</td>
<td>29</td>
<td>6</td>
<td>5 y</td>
</tr>
<tr>
<td>de Souza</td>
<td>2001</td>
<td>1990-1999</td>
<td>Sao Paulo, Brazil</td>
<td>Prospective, 1 centre</td>
<td>29</td>
<td>28</td>
<td>28</td>
<td>3.3 y</td>
</tr>
<tr>
<td>Ntusi</td>
<td>2015</td>
<td>1996-2009</td>
<td>Cape Town, South Africa</td>
<td>Prospective, 1 centre</td>
<td>30</td>
<td>31</td>
<td>17</td>
<td>3.5 y</td>
</tr>
<tr>
<td>Li</td>
<td>2016</td>
<td>2004-2011</td>
<td>Beijing, China</td>
<td>Retrospective, 1 centre</td>
<td>71</td>
<td>28</td>
<td>0</td>
<td>3.6 y</td>
</tr>
<tr>
<td>Cuenza</td>
<td>2016</td>
<td>2005-2015</td>
<td>Quezon City, Philippines</td>
<td>Retrospective, 1 centre</td>
<td>39</td>
<td>28</td>
<td>26</td>
<td>4.5 y</td>
</tr>
<tr>
<td>Akil</td>
<td>2016</td>
<td>2002-2012</td>
<td>Turkey</td>
<td>Retrospective, 3 centre</td>
<td>58</td>
<td>31</td>
<td>15</td>
<td>2.7 y</td>
</tr>
<tr>
<td>Author</td>
<td>Year</td>
<td>Time Period</td>
<td>Location</td>
<td>Study Design</td>
<td>Total</td>
<td>Stage 1</td>
<td>Stage 2</td>
<td>Stage 3</td>
</tr>
<tr>
<td>---------</td>
<td>-------</td>
<td>-------------</td>
<td>----------</td>
<td>--------------------</td>
<td>--------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Biteker</td>
<td>2012</td>
<td>2005-2009</td>
<td>Istanbul, Turkey</td>
<td>Prospective, 2 centre</td>
<td>42</td>
<td>27</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Duran</td>
<td>2008</td>
<td>1995-2007</td>
<td>Istanbul, Turkey</td>
<td>Prospective + retrospective, 1 centre</td>
<td>33</td>
<td>32</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>Mouquet</td>
<td>2012</td>
<td>1999-2006</td>
<td>Lille, France</td>
<td>Prospective, 1 centre</td>
<td>8</td>
<td>28</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Year</td>
<td>Period</td>
<td>Location</td>
<td>Study Design</td>
<td>N</td>
<td>Median FUP</td>
<td>Max FUP</td>
<td>Median Age (y)</td>
</tr>
<tr>
<td>------------</td>
<td>------</td>
<td>--------------</td>
<td>---------------------</td>
<td>----------------------</td>
<td>-------</td>
<td>------------</td>
<td>---------</td>
<td>----------------</td>
</tr>
<tr>
<td>Pillarisetti</td>
<td>2014</td>
<td>1999-2012</td>
<td>Kansas + Michigan, USA</td>
<td>Retrospective, 2 centre</td>
<td>100</td>
<td>30</td>
<td>11</td>
<td>8.2 y</td>
</tr>
<tr>
<td>Harper</td>
<td>2012</td>
<td>2002-2004</td>
<td>North Carolina, USA</td>
<td>Retrospective, population</td>
<td>85</td>
<td>NA</td>
<td>17</td>
<td>7 y</td>
</tr>
<tr>
<td>Felker</td>
<td>2000</td>
<td>1982-1997</td>
<td>Baltimore, USA</td>
<td>Retrospective, 1 centre</td>
<td>42</td>
<td>29</td>
<td>7</td>
<td>8.6 y</td>
</tr>
<tr>
<td>Adesanya</td>
<td>1989</td>
<td>1969-1972</td>
<td>Zaria, Nigeria</td>
<td>Prospective, 1 centre</td>
<td>181</td>
<td>NA</td>
<td>26</td>
<td>10 y</td>
</tr>
<tr>
<td>Chee</td>
<td>2013</td>
<td>2000-2009</td>
<td>Kuala Lumpur, Malaysia</td>
<td>Retrospective, 1 centre</td>
<td>12</td>
<td>32</td>
<td>8</td>
<td>6.4 y</td>
</tr>
<tr>
<td>Mishra</td>
<td>2006</td>
<td>1995-2005</td>
<td>Cuttack Orissa, India</td>
<td>Prospective, NA</td>
<td>56</td>
<td>31</td>
<td>23</td>
<td>6.1 y</td>
</tr>
<tr>
<td>Lamparter</td>
<td>2007</td>
<td>1989-2003</td>
<td>Marburg, Germany</td>
<td>Prospective, registry</td>
<td>10</td>
<td>30</td>
<td>0</td>
<td>5.8 y</td>
</tr>
</tbody>
</table>
Table 2: Studies of PPCM patients undergoing a subsequent pregnancy

<table>
<thead>
<tr>
<th>First author</th>
<th>Year</th>
<th>Number</th>
<th>Pregancies</th>
<th>Number of deaths in unrecovered LV function (% of total deaths)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sutton(^a)</td>
<td>1991</td>
<td>4</td>
<td>4 (100)</td>
<td>0</td>
</tr>
<tr>
<td>Witlin(^a)</td>
<td>1997</td>
<td>6</td>
<td>NA</td>
<td>1 (17)</td>
</tr>
<tr>
<td>Albanesi Filho(^b)</td>
<td>1999</td>
<td>12</td>
<td>6 (50)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>de Souza(^a)</td>
<td>2001</td>
<td>7</td>
<td>NA</td>
<td>0</td>
</tr>
<tr>
<td>Elkayam(^c)</td>
<td>2001</td>
<td>44</td>
<td>28 (64)</td>
<td>3 (7)</td>
</tr>
<tr>
<td>Avila(^b)</td>
<td>2002</td>
<td>18</td>
<td>7 (39)</td>
<td>1 (6)</td>
</tr>
<tr>
<td>Sharieff(^b)</td>
<td>2003</td>
<td>9</td>
<td>2 (22)</td>
<td>2 (22)</td>
</tr>
<tr>
<td>Sliwa(^d)</td>
<td>2004</td>
<td>6</td>
<td>2 (33)</td>
<td>2 (33)</td>
</tr>
<tr>
<td>Chapa(^a)</td>
<td>2005</td>
<td>6</td>
<td>4 (67)</td>
<td>0</td>
</tr>
<tr>
<td>Fett(^b)</td>
<td>2006</td>
<td>15</td>
<td>1 (7)</td>
<td>1 (7)</td>
</tr>
<tr>
<td>Mishra</td>
<td>2006</td>
<td>9</td>
<td>NA</td>
<td>5 (56)</td>
</tr>
<tr>
<td>Hilfiker-Kleiner(^c)</td>
<td>2007</td>
<td>12</td>
<td>12 (100)</td>
<td>3 (25)</td>
</tr>
<tr>
<td>Habli</td>
<td>2008</td>
<td>37</td>
<td>21 (67)</td>
<td>0</td>
</tr>
<tr>
<td>Modi(^c)</td>
<td>2009</td>
<td>NA</td>
<td>4 (27)</td>
<td>0</td>
</tr>
<tr>
<td>Chee(^c)</td>
<td>2009</td>
<td>2</td>
<td>2 (100)</td>
<td>0</td>
</tr>
<tr>
<td>Fett(^e)</td>
<td>2010</td>
<td>56</td>
<td>29 (52)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Mandal(^f)</td>
<td>2011</td>
<td>6</td>
<td>5 (83)</td>
<td>1 (17)</td>
</tr>
<tr>
<td>Hilfiker-Kleiner(^c)</td>
<td>2017</td>
<td>34</td>
<td>18 (53)</td>
<td>4 (12)</td>
</tr>
</tbody>
</table>

\(^a\) Number without therapeutic abortion  
\(^b\) Fractional shortening 30% used as cut off  
\(^c\) EF 50% used as cut off  
\(^d\) EF 40% used as cut off  
\(^e\) EF 55% used as cut off  
\(^f\) EF 45% used as cut off  
\(^\) at last follow-up  
\(^\) denominator is number of pregnancies  
\(^\) at last follow-up with follow-up data  
\(^\) n=32 with follow-up data  
\(^\) n=9 with follow-up data
**Figure 1: Management of women with PPCM and a subsequent pregnancy**

**General Maternal Health Factors**
- Age < 18 or Age > 35
- Poor maternal education
- Low household income
- Long distance to appropriate care
- Late presentation ( > 20 weeks)

**PPCM with partially or fully recovered LV function (LVEF>50%)**
- Substantial risk of relapse with subsequent pregnancy
- Risk of heart failure or death (<10%)
- Usually good fetal outcome

**PPCM with poorly recovered LV function (LVEF<50%)**
- High risk of relapse with subsequent pregnancy
- Risk of heart failure or death (>10%)
- Risk of premature delivery
- Risk of fetal death

**Specific management**
- Pregnancy can continue but some risks remain
  - Bromocriptine: consider post partum
  - Admission to high-care unit if in decompensated heart failure

**General Management**
- Referral to experienced centre
- Careful counselling of risk
- Close monitoring by cardiac-obstetric-anaesthetic team
- Monthly echocardiograms
- NT-ProBNP monitoring pre- and postpartum
- Careful post partum care
- Contraception advice post partum

**Specific management**
- Physicians should advise against pregnancy especially if LVEF < 30%
- **BOARD:**
  - Bromocriptine: strongly consider post partum
  - Oral Heart failure
  - Anticoagulation
  - Relaxant: vasodilators
  - Diuretics
• Adequate post diagnosis counselling, including future pregnancies and prognosis
• Counselling and education of families
• Prescription of formula milk provided if women is not breastfeeding
• Adequate dose of heart failure medication
• Contraceptive advice provided
• Referral to appropriate centre if unable to come back to expert centre
• Referred to social worker if unable to work/low income circumstances

Figure 2: Post Discharge Check Box for women diagnosed with PPCM
Contraception (Female)

- Intrauterine contraceptive device (e.g. Mirena or copper IUCDs)
- Oral contraceptive (combined or progestin only pills)
- Depomedroxyprogesterone acetate (DMPA) injections
- Tubal ligation
- Diaphragm
- Contraceptive implants
- Contraceptive patch
- Hysteroscopic tubal occlusion (HTO)
- Vaginal ring
- Safe period

Contraception (Male)

- Condom
- Vasectomy

Figure 3: Types of contraception